Alnylam Pharmaceuticals, Inc. (ALNY)

368.78 +3.32 (+0.91%) USD  |  NASDAQ  |  Jan 22, 15:35
More

Alnylam Pharmaceuticals Revenue Estimates for Next Fiscal Year

Revenue Estimates for Next Fiscal Year Chart

View Revenue Estimates for Next Fiscal Year for ALNY.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Revenue Estimates for Next Fiscal Year Chart
Start Trial

Historical Data

View Historical Data
Start Trial

Revenue Estimates for Next Fiscal Year Range, Past 5 Years

View Revenue Estimates for Next Fiscal Year Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue Estimates for Next Fiscal Year Benchmarks

View Revenue Estimates for Next Fiscal Year Benchmarks
Start Trial
Insmed, Inc. Upgrade
Pfizer Inc. Upgrade
Biogen, Inc. Upgrade
Bristol Myers Squibb Co. Upgrade
Vertex Pharmaceuticals, Inc. Upgrade

Revenue Estimates for Next Fiscal Year Related Metrics

Revenue Estimates for Current Quarter Upgrade
Revenue Estimates for Next Quarter Upgrade
Revenue Estimates for Current Fiscal Year Upgrade
EPS Estimates for Current Quarter Upgrade
EPS Estimates for Next Quarter Upgrade
EPS Estimates for Current Fiscal Year Upgrade
EPS Estimates for Next Fiscal Year Upgrade